The Specific Aims of the proposal are: 1) To dissect the role of PI3-K in the regulation of signalling protein (MEK and MAPK) activation in hematopoietic cells using constitutively active and dominant negative PI3-K mutants. 2) To biochemically and genetically identify the novel MEK activator in the wortmannin-sensitive, IL-3-inducible MEK activation pathway. 3) To determine the roles of MEK and MAPK and upstream regulators in hematopoietic cell proliferation and survival using transient and long-term proliferation assays. These studies are designed to characterize a discreet wortmannin-sensitive MAPK activation pathway that based on preliminary data may have cell type-specific components. Once identified these components will provide novel signal-transducing targets for pharmacological intervention to block cytokine-dependent proliferation of leukemic and normal myeloid lineage cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA073622-04
Application #
6172890
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Mccarthy, Susan A
Project Start
1997-04-05
Project End
2002-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
4
Fiscal Year
2000
Total Cost
$103,268
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Rust, C; Karnitz, L M; Paya, C V et al. (2000) The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem 275:20210-6
Sutor, S L; Vroman, B T; Armstrong, E A et al. (1999) A phosphatidylinositol 3-kinase-dependent pathway that differentially regulates c-Raf and A-Raf. J Biol Chem 274:7002-10